US biotech major Amgen is the latest drugmaker to announce direct-to-consumer access of medicines, adding to the first such ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S ...
Repatha (evolucumab) is now avaliable at a discounted cash price through Amgen's new direct-to-patient program, AmgenNow, and ...
Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha. This follows landmark results demonstrating ...
Pharmaceutical Technology on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
US biotech Amgen (Nasdaq: AMGN) has reported that its cholesterol therapy Repatha (evolocumab) hit both primary endpoints in ...
In a recent column, you wrote about reducing cholesterol with the help of statins along with a PCSK9i, such as Repatha or Praluent. My question is: Are these PCSK9is at all beneficial if one cannot ...
Amgen (AMGN) stock is in focus as its cholesterol drug Repatha succeeds in a Phase 3 trial, reducing the risk of major ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback